FIELD: organic chemistry.
SUBSTANCE: invention relates to an immunomodulator which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, where X1 is S; S(O) or S(O)2; X2 is N or C(R4); R1 denotes H or methyl; R2 denotes phenyl; pyridinyl; quinolinyl or thiadiazolyl, where R2 is optionally substituted with one or more R5, which are identical or different; R5 is halogen; CN; OR6; C(O)N(R6R6a); T1 or C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogens which are the same or different; R6, R6a are independently selected from a group consisting of H and C1-6 alkyl, where C1-6 alkyl is optionally substituted with one or more halogens, which are identical; T1 is C3-7 cycloalkyl; oxadiazolyl; thiadiazolyl; triazolyl or morpholinyl, where T1 is optionally substituted with one R7; R7 represents C1-6 alkyl; R3 is R3a; OR3a; NHR3a or NHC(O)R3a; R3a is T2; C1-12 alkyl; C2-12 alkenyl or C2-12 alkynyl, where C1-12 alkyl; C2-12 alkenyl and C2-12 alkynyl are optionally substituted with one or three R9, which are identical or different; R9 is halogen; OR10; C(O)N(R10R10a); N(R10)C(O)R10a; T2 or C1-12 alkyl; R10, R10a are independently selected from a group consisting of H or C1-12 alkyl, where C1-12 alkyl is optionally substituted with one R11; T2 is phenyl; C3-7 cycloalkyl; oxanyl; morpholinyl; oxazolyl; pyridinyl; oxolanyl or oxaspiroheptanyl, where T2 is optionally substituted with one or two R12, which are identical or different; R12 is halogen; OR13; OC(O)N(R13R13a); T3 or C1-6 alkyl, where C1-6 alkyl is optionally substituted with one to three R14, which are identical or different; R13, R13a are independently selected from a group consisting of H; C1-6 alkyl; C2-6 alkenyl and C2-6 alkynyl, where C1-6 alkyl is optionally substituted with one or more R14, which are identical; R11, R14 are independently selected from a group consisting of halogen; OR15; C(O)N(R15R15a); or N(R15)C(O)R15a; R15, R15a are independently selected from a group, consisting of H and C1-6 alkyl ; T3 is phenyl or morpholinyl; R4 is H; F; Cl or N (CH3)2; R18 is H or C1-6 alkyl, where C1-6 alkyl is optionally substituted with one R19; R19 is N (R20)C(O)OR20a; R20, R20a are independently selected from a group consisting of H and C1-6 alkyl. Invention also relates to a pharmaceutical composition based on the compound of formula (I).
EFFECT: technical result is obtaining novel compounds and a pharmaceutical composition based thereon, which can be used in medicine for treating cancer.
23 cl, 47 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| BENZOTHIAZEPINE COMPOUNDS AND USE THEREOF AS BILE ACID MODULATORS | 2020 |
|
RU2817535C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | 2011 |
|
RU2565596C2 |
| AZADECALINS CONDENSED WITH HETEROARYLKETONES - GLUCOCORTICOID RECEPTOR MODULATORS | 2013 |
|
RU2639867C2 |
| AZABICYCLIC AND DIAZEPINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS | 2018 |
|
RU2795521C2 |
| COMPOUNDS OF THIENOPYRIMIDINE | 2013 |
|
RU2637925C2 |
| PYRAZINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2809631C2 |
| DERIVATIVES OF CYCLOHEXANE OR TETRAHYDROPYRANE OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, OR HYDRATES, OR SOLVATES OF THESE COMPOUNDS, OR THEIR SALTS, INTERMEDIATE COMPOUNDS FOR THEIR SYNTHESIS AND FUNGICIDE AGENT | 1992 |
|
RU2084439C1 |
| ISOINDOLINONE INHIBITORS OF MDM2-P53 INTERACTION WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2794333C1 |
